Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Cystic fibrosis (CF) is a disease caused by a mutation in the gene that makes the cystic
fibrosis transmembrane regulator protein. As a result mucus stagnation, obstruction and
plugging take place in the respiratory and gastrointestinal tract, the biliary and pancreatic
duct, and in the reproductive system. The objective of this study is to determine the safety
and tolerability of 3 days of daily dosing of OligoG CF-5/20 versus placebo in healthy
volunteers.